§ 522.1335 Medetomidine hydrochloride injection.

(a) Specifications. Each milliliter of sterile aqueous solution contains 1.0 milligram of medetomidine hydrochloride.

(b) Sponsor. See 052483 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 750 micrograms intravenously (IV) or 1,000 micrograms intramuscularly per square meter of body surface. The IV route is more efficacious for dental care.

(2) Indications for use. As a sedative and analgesic in dogs over 12 weeks of age to facilitate clinical examinations, clinical procedures, minor surgical procedures not requiring muscle relaxation, and minor dental procedures not requiring intubation. The intravenous route of administration is more efficacious for dental care.

(3) Limitations. Do not use in dogs with cardiac disease, respiratory disorders, liver or kidney diseases, dogs in shock, dogs which are severely debilitated, or dogs which are stressed due to extreme heat, cold, or fatigue. Allow agitated dogs to rest quietly before administration. Do not repeat dosing in dogs not responding satisfactorily to treatment. Do not use in breeding or pregnant animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[61 FR 21075, May 9, 1996]

§ 522.1350 Melatonin implant.

(a) Specifications. The drug is a silicone rubber elastomer implant containing 2.7 milligrams of melatonin.

(b) Sponsor. See No. 053923 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. One implant per mink.

(2) Indications for use. For use in healthy male and female kit and adult female mink (Mustela vison) to accelerate the fur priming cycle.

(3) Limitations. For subcutaneous implantation in mink only. Do not implant potential breeding stock. Do not use in food-producing animals.

[60 FR 49340, Sept. 25, 1995]

§ 522.1362 Melarsomine dihydrochloride for injection.

(a) Specifications. The drug consists of a vial of lyophilized powder containing 50 milligrams of melarsomine dihydrochloride which is reconstituted with the provided 2 milliliters of sterile water for injection.

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. For asymptomatic to moderate (class 1 to class 2) heartworm disease: 2.5 milligrams per kilogram of body weight (1.1 milligram per pound) twice, 24 hours apart. The series can be repeated in 4 months depending on the response to the first treatment and the condition, age, and use of the dog. For severe (class 3) heartworm disease: Single injection of 2.5 milligrams per kilogram followed, approximately 1 month later, by 2.5 milligrams per kilogram administered twice, 24 hours apart.

(2) Indications. Treatment of stabilized, class 1, 2, and 3 heartworm disease (asymptomatic to mild, moderate, and severe, respectively) caused by immature (4 month-old, stage L₅) to mature adult infections of Dirofilaria immitis in dogs.

(3) Limitations. Administer only by deep intramuscular injection in the lumbar muscles (L₃-L₅). Use a 23 gauge 1 inch needle for dogs less than or equal to 10 kilograms (22 pounds) and a 22 gauge 1 1/2 inch needle for dogs greater than 10 kilograms (22 pounds). Use alternate sides with each administration. The drug is contraindicated in dogs with class 4 (very severe) heartworm disease (Caval Syndrome). Not for use in breeding animals and lactating or pregnant bitches. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[60 FR 49340, Sept. 25, 1995]

§ 522.1367 Meloxicam.

(a) Specifications. Each milliliter of solution contains 5.0 milligrams (mg) meloxicam.

(b) Sponsor. See No. 000010 in § 510.600(c) of this chapter.